Dermata Therapeutics Inc.

NASDAQ: DRMA · Real-Time Price · USD
0.77
0.03 (4.19%)
At close: Apr 28, 2025, 3:58 PM
0.73
-5.88%
After-hours: Apr 28, 2025, 07:55 PM EDT

Company Description

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions.

The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.

It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions.

The company was incorporated in 2014 and is headquartered in San Diego, California.

Dermata Therapeutics Inc.
Dermata Therapeutics Inc. logo
Country United States
IPO Date Aug 13, 2021
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Gerald T. Proehl

Advertisement

Contact Details

Address:
3525 Del Mar Heights Road
San Diego, California
United States
Website https://www.dermatarx.com

Stock Details

Ticker Symbol DRMA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001853816
CUSIP Number 249845108
ISIN Number US2498453065
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Gerald T. Proehl Founder, President, Chief Executive Officer & Chairman
Kyri K. Van Hoose CPA, M.B.A. Senior Vice President & Chief Financial Officer
David F. Hale Co-Founder & Lead Independent Director
Dr. Christopher J. Nardo M.P.H., Ph.D. Senior Vice President & Chief Development Officer
Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. Senior Vice President of Regulatory Affairs & Quality Assurance
Sean Proehl Associate General Counsel

Latest SEC Filings

Date Type Title
Apr 23, 2025 424B3 Filing
Apr 15, 2025 S-3 Filing
Apr 15, 2025 8-K Current Report
Apr 07, 2025 SCHEDULE 13D/A [Amend] Filing
Apr 03, 2025 SCHEDULE 13D/A [Amend] Filing
Mar 28, 2025 8-K Current Report
Mar 27, 2025 8-K Current Report
Mar 25, 2025 8-K Current Report
Mar 17, 2025 8-K Current Report
Mar 17, 2025 10-K Annual Report